Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has earned an average recommendation of “Hold” from the seven research firms that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $14.50.

Separately, ValuEngine downgraded Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc raised its stake in shares of Aquinox Pharmaceuticals by 2.9% in the third quarter. Vanguard Group Inc now owns 342,574 shares of the company’s stock worth $1,004,000 after purchasing an additional 9,682 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Aquinox Pharmaceuticals in the third quarter worth $95,000. EcoR1 Capital LLC raised its stake in shares of Aquinox Pharmaceuticals by 97.0% in the third quarter. EcoR1 Capital LLC now owns 2,265,880 shares of the company’s stock worth $6,639,000 after purchasing an additional 1,115,880 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Aquinox Pharmaceuticals in the third quarter worth $136,000. Finally, Highbridge Capital Management LLC raised its stake in shares of Aquinox Pharmaceuticals by 66.3% in the third quarter. Highbridge Capital Management LLC now owns 480,108 shares of the company’s stock worth $1,407,000 after purchasing an additional 191,490 shares during the last quarter. 77.55% of the stock is owned by hedge funds and other institutional investors.

NASDAQ AQXP traded down $0.07 during trading on Monday, hitting $2.32. 1,122 shares of the company’s stock were exchanged, compared to its average volume of 48,495. Aquinox Pharmaceuticals has a fifty-two week low of $1.96 and a fifty-two week high of $16.90.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its earnings results on Thursday, November 8th. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.43).

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.

Featured Story: Penny Stocks, What You Need To Know

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.